Trial Profile

A phase III clinical trial of MS1819

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 29 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adrulipase alfa (Primary)
Indications Exocrine pancreatic insufficiency
Focus Proof of concept; Registrational; Therapeutic Use
Sponsors AzurRx BioPharma; Entero Therapeutics

Most Recent Events

16 May 2024 According to an Entero Therapeutics media release, First Wave Biopharma has changed its name to Entero Therapeutics.
10 Nov 2020 According to an AzurRx Biopharma media release, company Identified Asymchem as potential partner of choice for MS1819 phase 3 clinical trial drug production.
28 Apr 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com